Table 2.
ASD patients with absent or suboptimal seroconversion after booster administration of COVID-19 vaccine.
| ASD Patients |
NAb anti-COVID-19 |
||||||
|---|---|---|---|---|---|---|---|
| Sex/ | serum titer after | ||||||
| no. | Age | Diagnosis | Main Symptoms° | Treatments* | COVID-19 vaccine | 6 months | Booster dose |
| Non response | |||||||
| 1 | F/57 | SSc | dcSSc, SU | MMF, low dose CS | nr | nr | nr |
| 2 | F/57 | SSc | dcSSc, arthritis | MTX, ABA, low dose CS | nr | nr | nr |
| 3 | F/52 | SSc | dcSSc, overlapping SLE | RTX, low dose CS | nr | nr | nr |
| 4 | F/43 | SSc | dcSSc, ILD, SU | MMF, RTX, low dose CS | nr | nr | nr |
| 5 | F/52 | SSc | lcSSc, overlapping SLE | MMF | nr | nr | nr |
| 6 | M/83 | CV | SU, purpura, peripheral neuropathy | high dose CS | nr | nr | nr |
| 7 | F/78 | CV | SU, purpura, peripheral neuropathy, hyperviscosity s. | RTX | nr | nr | nr |
| 8 | F/72 | CV | purpura, B-NHL | Chemiotherapy | nr | nr | nr |
| 9 | M/75 | RA | polyarthritis | MTX, low dose CS | nr | nr | nr |
| Suboptimal response | |||||||
| 10 | M/60 | RA | polyarthritis | MTX | sub | sub | sub |
| 11 | F/45 | RA | overlapping SLE | RTX, HCQ, low dose CS | nr | nr | sub |
| 12 | M/73 | RA | polyarthritis, ILD | HCQ, low dose CS | sub | 286.5 | sub |
| 13 | F/74 | RA | polyarthritis, ILD | JAK, low dose CS | nr | nr | sub |
| 14 | F/22 | SLE | polyarthritis, thyroiditis | BEL, CyA, HCQ, low dose CS | 115.4 | nr | sub |
| 15 | F/86 | SSc | lcSSc, ILD, K | low dose CS | sub | nr | sub |
| 16 | F/71 | SSc | lcSSc | HCQ | 140.2 | sub | sub |
| 17 | F/56 | SSc | dcSSc, ILD | MMF | 768 | sub | sub |
| 18 | F/54 | SSc | lcSSc | MMF, RTX** | 675,7 | nr | sub |
| 19 | M/75 | CV | purpura, SU | RTX, low dose CS | nr | nr | sub |
ASD: autoimmune systemic diseases; COVID-19: coronavirus disease 2019; RA: rheumatoid arthritis; SSc: systemic sclerosis; SLE: systemic lupus erythematosus; CV: cryoglobulinemic vasculitis; lcSSc: limited cutaneous SSc; dcSSc: diffuse cutaneous SSc; SU: skin ulcers; ILD: interstitial lung disease; NAb: neutralizing antibodies; titre of NAb: BAU/mL; nr: non response (<7 BAU/mL); sub: suboptimal response (<70 BAU/mL) to COVID-19 vaccine. *treatments within the last 6 months and during the vaccination cycle: MTX: methotrexate; RTX: rituximab; MMF: mycophenolate mofetyl; ABA: abatacept; JAK: Janus kinase inhibitors; BEL: belimumab; CyA: cyclosporin A; TNF: anti-TNF-alpha inhibitors; HCQ: hydroxychloroquine; CS: corticosteroids; **RTX cycle administered after the first 2 doses of vaccine; nr: non-responder; sub: sub-optimal responder.